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Abstract
Background: A new molecular marker of carcinoma in the urinary bladder is needed as a diagnostic tool or as a
therapeutic target. Potential markers include microRNAs (miRNAs), which are short, low molecular weight RNAs
19–24 nt long that regulate genes associated with cell proliferation, differentiation, and development in various
cancers. In this study, we investigated the molecular mechanisms by which miR-145 promotes survival of urothelial
carcinoma cells and differentiation into multiple lineages. We found miR-145 to regulate expression of syndecan-1,
a heparin sulfate proteoglycan.
Methods: Cell proliferation in the human urothelial carcinoma cell lines T24 and KU7 was assessed by MTS assay.
Cellular senescence and apoptosis were measured by senescence-associated β-galactosidase (SA-β-gal) and TUNEL
assay, respectively. Quantitative RT-PCR was used to measure mRNA expression of various genes, including syndecan-1,
stem cell factors, and markers of differentiation into squamous, glandular, or neuroendocrine cells.
Results: Overexpression of miR-145 induced cell senescence, and thus significantly inhibited cell proliferation in T24
and KU7 cells. Syndecan-1 expression diminished, whereas stem cell markers such as SOX2, NANOG, OCT4, and E2F3
increased. miR-145 also up-regulated markers of differentiation into squamous (p63, TP63, and CK5), glandular
(MUC-1, MUC-2, and MUC-5 AC), and neuroendocrine cells (NSE and UCHL-1). Finally, expression of miR-145 was
down-regulated in high-grade urothelial carcinomas, but not in low-grade tumors.
Conclusions: Results indicate that miR-145 suppresses syndecan-1 and, by this mechanism, up-regulates stem
cell factors and induces cell senescence and differentiation. We propose that miR-145 may confer stem cell-like
properties on urothelial carcinoma cells and thus facilitate differentiation into multiple cell types.
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Background
Urinary bladder cancer is a common malignant tumor
with high mortality. Thus, well characterized biomarkers
are needed to screen, diagnose and manage bladder can-
cer. Over the years, a number of studies have examined
molecular mechanisms of urothelial carcinoma progres-
sion, as well as diagnostic tools and therapeutic strat-
egies [1, 2]. However, useful diagnostic markers that
predict clinical outcome have not been found. Potential
new biomarkers include microRNAs (miRNAs), which
are small non-coding RNAs that regulate gene expres-
sion by suppressing protein translation or by promoting
degradation of messenger RNA [3]. Therefore, investiga-
tion of miRNAs and their targets could provide both
novel therapeutic targets as well as diagnostic markers
of the development, progression, differentiation, and
metastatic potential of malignant tumors. Indeed, some
miRNAs are abundantly expressed and act as tumor
suppressors. MiRNAs such as miR-1, 100, 101, 133, and
192 are down-regulated in several cancers and promote
cell proliferation, migration and invasion [4–7].
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Syndecan-1 is expressed in a majority of epithelial and
nonepithelial neoplasms, and is involved in cell growth,
adhesion, migration, epithelial morphogenesis, and angio-
genesis [8–10]. We previously reported that this proteo-
glycan transforms androgen-dependent prostate cancer
cells into androgen-independent tumors and facilitates
progression [11, 12]. Moreover, syndecan-1 and the miR-
NAs miR-126 and, 149 regulate cell proliferation through
down-regulation of several stem cell factors such as SOX2,
NANOG, and OCT4 [13]. Finally, syndecan-1 was de-
tected in plasmacytoid urothelial carcinoma, an aggressive
tumor [14–18], demonstrating that the protein is closely
associated with urothelial carcinoma progression [19].
In this study, we demonstrate that miR-145 in blad-
der cancer cells down-regulates syndecan-1 expression,
inhibits cell proliferation by inducing senescence, and
promotes differentiation into glandular, squamous, and
neuroendocrine cells. Moreover, miR-145 and syndecan-1
were found to be up-regulated in low-grade urothelial car-
cinoma, but not in high-grade tumors.
Methods
Cell lines
The human urothelial carcinoma cell lines, T24 was
purchased from American Type Culture Collection
(Manassas, VA), and KU7 was derived from human
papillary bladder cancer [20]. T24 and KU7 were cultured
in RPMI1640 media supplemented with 10 % fetal bovine
serum and 50 units/mL penicillin-streptomycin at 37 °C
in 5 % CO2.
Transfection
T24 or KU7 were seeded at a density of 1x104 cells/well
and transfected for 72 h with Anti-miR™ miRNA Inhibi-
tor, Pre-miR™ miRNA Precursor (hsa-miR-145, Life
Technologies), or 100 ng/L siRNA against syndecan-1.
Transfection was performed in Lipofectamine RNAi-
MAX (Life Technologies) according to the manufac-
turer’s protocol. The sequence of the syndecan-1 siRNA
was 5′-TCCGACTGCTTTGGACCTAAA-3′.
Quantitative RT-PCR
Total RNA, including miRNA, was extracted from cells
using the miRNeasy Mini kit (QIAGEN). First-strand
cDNA was synthesized from 1 μg total RNA using Pri-
meScript RT Master Mix (Perfect Real Time, TaKaRa),
TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems) and TaqMan MicroRNA Assays (Applied
Biosystems), respectively. real-time PCR was performed
using SYBR Premix Ex Taq II (TliRNaseH Plus, TaKaRa)
and TaqMan Universal PCR Master Mix II (Applied Bio-
systems), respectively. Templates were initially denatured
at 95 °C for 30 s, and targets were amplified over 35–45
PCR cycles at 55-63 °C (Table 1).
Cell proliferation
CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega) was used for MTS assay as previously
described [11] to measure cell proliferation. Data were
collected from triplicate experiments.
Senescence-associated β-galactosidase (SA-β-gal) assay
and TdT-mediated dUTP nick end labeling (TUNEL) assay
SA-β-gal was measured using Senescence Detection Kit
(BioVision, CA) in T24 cells transfected for 72 h with
miR-145 precursor. The assay was performed according
to the kit manual. Similarly, T24 cells transfected with
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miR-145 precursor for 72 h were harvested and stained
with ApopTag Plus Peroxidase In Situ Apoptosis Detec-
tion Kit (Millipore Corporation, CA).
Tissue samples
We examined fifteen trans-urethral resection of bladder
tumor specimens without undergoing chemotherapy or
Bacillus Calmette-Guerin treatment (age: 51–84 years,
grade: low grade 5 cases; high grade 10 cases). The
present study received ethics committee approval of
Nara Medical University (NMU900). The informed con-
sent was obtained from all patients. All tissue samples
were fixed in 10 % formalin for 48 h and processed
through graded alcohols to paraffin. Paraffin blocks were
sectioned at 3-μm intervals and stained with hematoxylin
and eosin (HE) for histological diagnosis. For each HE
stained sample, corresponding sections, to include cancer
foci of interest, were cut at 8-μm intervals for extraction
of total RNA. Tumor stage and grade were noted at the
time of diagnosis by two independent urological patholo-
gists (KS and NK) (Fig. 4a). Total RNA, including miRNA,
was purified from paraffin-embedded tissue sections using
miRNeasy FFPE kit (QIAGEN). First-strand cDNA was
synthesized using TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems), and real-time PCR was per-
formed using TaqMan MicroRNA Assays and TaqMan
Universal PCR Master Mix II (Applied Biosystems) to
amplify miR-145 and RNU6B.
Informed consent was obtained from patients as ap-
propriate before specimens were collected. The study
was approved by the ethics committee at Nara Medical
University.
Statistical analysis
Differences in measures of continuous variables were an-
alyzed using ANOVA or the nonparametric Mann–
Fig. 1 a MTS assay in T24 and KU7 cells. Cell proliferation was suppressed by transient transfection of miR-145 precursor. (inh:inhibitor, pre:precursor)
The cell counts was also lower in miR-145 precursor transfected T24 cells (48 h). b Papanicolaou stain (upper panel), SA-β-gal (middle panel) and TUNEL
(lower panel) assay. Papanicolaou stain of T24 cells showed slightly enlarged by transient transfection of miR-145 precursor in T24 cells. Senescent cells
with SA-β-galactosidase activity was significantly induced, on the other hand, apoptotic cells were not increased by miR-145 overexpression (*p < 0.05)
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Whitney and Kruskal-Wallis tests. Results were analyzed
using one-way ANOVA and Turkey’s post hoc test.
Two-tailed Student’s t test was used to compare two
data points. Results with p < 0.05 were considered
significant.
Results
miR-145 suppresses cell proliferation in bladder cancer
cells
We first examined whether miR-145 regulates cell prolif-
eration in urothelial carcinoma cells by transfecting the
miR-145 precursor into T24 and KU7 cells. Figure 1a
shows that miR-145 overexpression significantly sup-
pressed cell proliferation. To evaluate the mechanisms
underlying this suppression, SA-β-gal and TUNEL as-
says were performed. We found senescence to be in-
duced in overexpressing T24 cells, although the number
of apoptotic cells was not significantly increased (Fig. 1b).
Taken together, the data demonstrate that miR-145
regulates cell proliferation in urothelial carcinoma cells
by inducing senescence, but not apoptosis.
Expression of differentiation markers
miR-145 transfection slightly changed the morphological
characteristics of T24 and KU7 cells. Therefore, cells
were additionally transfected 48 and 72 h after initial
transfection. Figure 2a shows elongated axis feet in
transfected T24 cells. Cytoplasmic expansion is clearly
observed in samples stained with Papanicolaou stain
(Fig. 1b, upper panel). In addition, miR-145 transfection
increased mRNA expression of some differentiation
markers, including p63, TP63, and cytokeratin 5, which
are markers of squamous cells, as well as MUC-1,
MUC-2, and MUC-5 AC, which are markers of glandu-
lar cells. Neuroendocrine markers; neuron-specific eno-
lase (NSE) and ubiquitin carboxyl-terminal esterase L1
(UCHL-1) were also induced (Fig. 2 b-d, Additional file 1:
Figure S1A).
Fig. 2 a Morphological comparison of miR-145 precursor transfected T24 cells cultured under adherent conditions. b,c,d mRNA expression of
squamous markers (p63, TP63 and cytokeratin 5 : b, glandular markers (MUC-1, MUC-2 and MUC-5 AC : c and neuroendocrine markers (NSE and
UCHL-1 : d was increased under conditions of miR-145 overexpression in T24 cells. Y-axis in b,c and d was indicative of relative mRNA expression
compared with control. All mRNAs data were normalized by GAPDH. (*p < 0.05, miR-145 pre; miR-145 precursor)
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miR-145 significantly induces NANOG, SOX2, OCT4, and
E2F3
Morphological changes and induction of several differ-
entiation markers indicate that urothelial carcinoma cells
overexpressing miR-145 differentiate into various line-
ages. Accordingly, we found that stem cell markers such
as NANOG, OCT4, SOX2, and E2F3 were strongly in-
duced, but not CD44 (Fig. 3a, Additional file 1: Figure
S1B). miR-145 also induced E-cadherin, but not p53
(Fig. 3a, Additional file 1: Figure S1C). As reduced E-
cadherin expression is associated with high-grade, inva-
sive carcinomas, and correlates with poor prognosis
[21, 22], the data indicate that miR-145 facilitates dif-
ferentiation into various cell types, but not invasion.
miR-145 significantly decreases syndecan-1 expression
Overexpression of miR-145 significantly suppressed
syndecan-1 mRNA (Fig. 3b, Additional file 1: Figure
S1D). Similarly, silencing of syndecan-1 by siRNA up-
regulated some stem cell and differentiation markers
(Fig. 3c). Taken together, the data suggest that miR-145
regulates cell proliferation and differentiation in urothe-
lial carcinoma cells by down-regulating syndecan-1 while
up-regulating some stem cell markers.
Expression of miR-145 in clinical bladder cancer tissues
In vitro results imply that miR-145 is suppressive, and im-
pedes progression of urothelial carcinoma cells. Therefore,
miR-145 might be a novel marker to accurately detect car-
cinoma cells in surgical tissue specimens. Urothelial car-
cinoma was histologically classified into low grade, high
grade and high grade with squamous, glandular or neuro-
endocrine differentiation (Fig. 4a). Analysis of TUR tissue
specimens clearly shows that expression of miR-145 is
statistically lower in high-grade tumors than in low-
grade, non-invasive, or superficially invasive tumors
(Fig. 4b). These results suggest that miR-145 can be
used as a novel molecular marker for histological diag-
nosis of bladder cancer.
Discussion
In this study, we demonstrate for the first time that
miR-145 in bladder cancer cells suppresses syndecan-1
and thereby regulates cell proliferation and expression of
some markers of differentiation into squamous, glandu-
lar, and neuroendocrine cells. In addition, miR-145 in-
duces expression of stem cell markers such as SOX2,
OCT4, NANOG, and E2F3. Furthermore, the ability of
miRNAs to reprogram cancer cells into cells with stem
Fig. 3 a mRNA expression of stem cell markers (SOX2, NANOG, Oct4, and E2F3) was increased but not CD44 under conditions of overexpression
of miR-145 in T24 cells (Left panel). E-cadherin expression was increased, but not p53 under transfection of miR-145 precursor (Right panel). b
Syndecan-1 mRNA expression was suppressed by transfection of miR-145 precursor. c NANOG, MUC-1, TP63, NSE amd E-cadherin increased in
T24 cells following transient transfections of syndecan-1 siRNA. Y-axis in A, B and C was indicative of relative mRNA expression compared with
control. All mRNAs data were normalized by GAPDH. (*p < 0.05, miR-145 pre; miR-145 precursor)
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cell-like properties and low malignancy potential has
been previously demonstrated in colon cancer [23],
therefore miRNAs could regulate the fate of cancer cells.
These results are in line with our recently published
study, in which we demonstrate that syndecan-1, miR-
126, and miR-149 modulate cell senescence by control-
ling expression of SOX2, NANOG, and OCT4 [13].
Differentiation into squamous or glandular cells is a
hallmark of advanced-stage, invasive urothelial carcinomas
with poor prognosis [24–26]. An isoform of p63, a
marker of squamous cells, transactivates p53 target
genes and induces cell cycle arrest and apoptosis [25, 26].
Up-regulation of MUC-1, a marker of glandular cells, pro-
motes cell proliferation and invasion through epithelial-
to-mesenchymal transition in some late-stage carcinomas
including urothelial cancer [27–30]. UCHL-1 is overex-
pressed in pancreatic endocrine tumors, as well as in colo-
rectal and lung cancers. This enzyme is a neuroendocrine
marker that recognizes and hydrolyzes a peptide bond at
the C-terminus of ubiquitin, and remodels synapses by
controlling ubiquitin homeostasis [31–33]. In the current
study, miR-145 provided to suppress cell proliferation and
reverse urothelial carcinomas to the pluripotent cells
with stem cell features through induction of senes-
cence, then prompted differentiation to multiple line-
ages such as squamous, glandular and neuroendocrine
cells. Taken together, miR-145 might contribute to the
early step of divergent differentiation for invasive
urothelial carcinomas.
miR-145 appears to be a tumor suppressor, the expres-
sion of which is reduced in various carcinomas including
colon, lung, prostate, and breast cancer [34–37]. A
number of recent studies have focused on the role of
miR-145 in multiple cellular pathways underlying car-
cinogenesis. For example, miR-145 has been found to
inhibit cancer cell growth, invasion, and metastasis by
suppressing EGFR and NUDT1 in lung adenocarcin-
oma, FSCN-1 in esophageal squamous cell carcinoma,
N-cadherin in gastric carcinoma, and IGF in hepatocel-
lular carcinoma [38–41]. In our experiments, miR-145
Fig. 4 Expression of miR-145 in urothelial carcinoma tissues. a Urothelial carcinoma of the bladder tissues. Urothelial carcinomas were histologically
classified in to low grade and high grade (sq. diff.: squamous differentiation, gl. diff. :glandular differentiation, N.E. diff.: neuroendocrine differentiation)
(Hematoxylin-eosin staining). b qRT-PCR analysis of the urothelial carcinoma tissues showed that miR-145 highly expressed in low grade than high
grade carcinomas. (*p < 0.05, low grade v.s. high grade)
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expression in the urothelial carcinoma cell lines T24
and KU7 induces cell senescence without apoptosis.
We have previously shown syndecan-1 to be important
for the tumorigenicity and serial reproducibility of
prostatic tumor-initiating cells, as well as for forming
tumorigenic microspheres [12]. Indeed, syndecan-1 might
contribute to cell survival and progression, and is up-
regulated in urothelial carcinomas, particularly in high-
grade and aggressively invasive cancers [19]. Together
with these observations, miR-145 provides the basis for
differentiation into multiple cell types, and for suppression
of tumor-initiating cells.
Approximately 80 % of urothelial carcinomas are low-
grade and non-invasive, and about 70 % are multifocal
or recurrent with reasonably good prognosis [21]. In
contrast, high-grade and invasive cancers metastasize lo-
cally and distally. The capacity of such cancers to invade
other tissues depends on intrinsic genetic factors, such
as mutations in Ras or fibroblast growth factor receptor
3, as well as expression of p53 and RB tumor suppressor
[42]. Reduced E-cadherin expression compromises cell-
cell adhesion, and is histologically associated with high-
grade, invasive urothelial carcinoma [21]. However, our
data show that miR-145 overexpression induces E-
cadherin, but not p53, and that miR-145 is more abun-
dantly expressed in low-grade urothelial carcinomas
than in high-grade cancers. Therefore, miR-145 may
additionally suppress tumors by enhancing cell-cell ad-
hesion through E-cadherin. Notably, E-cadherin expres-
sion is negatively correlated with syndecan-1 expression,
which is in line with previous results [19].
Conclusion
In conclusion, miR-145 utilizes syndecan-1 to modulate
cell proliferation, re-programming, and differentiation
in urothelial carcinomas. Thus, miR-145 is a potential
diagnostic or prognostic marker, as well as a target for
therapy.
Additional file
Additional file 1: Figure S1. mRNA expression of differentiation markers,
stem cell markers and syndecan-1 in KU7 cells. Y-axis in A, B, C and D was
indicative of relative mRNA expression compared with control. All mRNAs
data were normalized by GAPDH. (A) mRNA expression of squamous
markers (p63 and TP63 ; left graph), glandular markers (MUC-1, MUC-2
and MUC-5 AC ; center graph) and neuroendocrine markers (NSE and
USHL-1 ; right graph) was increased under conditions of miR-145
overexpression in KU7 cells. (B) mRNA expression of stem cell markers
(SOX2, NANOG, OCT4, and E2F3) was increased, but not CD44 under
conditions of overexpression of miR-145 in KU7 cells. (C) E-cadherin
expression was increased, but not p53 under transfection of miR-145
precursor. (D) Syndecan-1 mRNA expression was suppressed by transfection of
miR-145 precursor. (*p< 0.05, miR-145 pre; miR-145 precursor). (JPEG 382 kb)
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